COMMUNIQUÉS West-GlobeNewswire

-
Breakthrough in Brain–Computer Interface Technology: A New Era of Neural Decoding at the Society for Neuroscience Annual Meeting, Neuroscience 2024
07/10/2024 -
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
07/10/2024 -
Colateral completes acquisition of Turbyne creating the first retail media operating system designed for in-store, that integrates with all channels and partners
07/10/2024 -
The JDRF Ride to Defeat Diabetes brings corporate Canada together to pedal for a cure for type 1 diabetes
07/10/2024 -
Le Roulons pour vaincre le diabète FRDJ rassemble les entreprises canadiennes pour pédaler vers la guérison du diabète de type 1
07/10/2024 -
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile
07/10/2024 -
Curia Unveils Brand Refresh at CPHI WW in Milan
07/10/2024 -
New York Medical Device Development Legacy Company MIDI Expands to Toronto
07/10/2024 -
Sanara MedTech Inc. Announces Changes to Its Board of Directors
07/10/2024 -
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
07/10/2024 -
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
07/10/2024 -
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
07/10/2024 -
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
07/10/2024 -
VIVUS Announces Commercialization of QSIVA® in Sweden, Denmark, Finland, Iceland, Norway, and Poland
07/10/2024 -
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
07/10/2024 -
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
07/10/2024 -
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
07/10/2024 -
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
07/10/2024 -
Route 92 Medical Files Patent Infringement Suit Against Q’Apel Medical
07/10/2024
Pages